Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-02T21:08:45.516Z Has data issue: false hasContentIssue false
  • English
  • Français

The Effect of Risperidone on Cognitive and Psychopathological Manifestations of Schizophrenia

Published online by Cambridge University Press:  07 November 2014

Isabelle Lussier  and
Emmanuel Stip
Get access Rights & Permissions [Opens in a new window]

Abstract

The purpose of this study was to evaluate the effect of risperidone on the cognitive functioning of patients with schizophrenia and how it relates to the alleviation of psychopathological symptoms usually observed in patients receiving treatment. Twelve schizophrenic patients were evaluated while being treated with a traditional neuroleptic, and again approximately 8 and 24 weeks after initiation of risperidone. Patients were compared with a group of normal controls (n=24) who underwent the same cognitive evaluation across time. The normal control group was included to evaluate the level of impairments in patients, but also to test for practice effects. The cognitive evaluation included measures of short-term and long-term memory; attention (alertness, sustained and selective); and executive functioning (verbal and category fluency). Clinical symptoms were rated on the Positive and Negative Symptoms Scale (PANSS) and the Brief Psychiatric Rating Scale (BPRS). Extrapyramidal symptoms were rated with the Extrapyramidal Symptoms Rating Scale.

During treatment with risperidone, schizophrenic patients improved their BPRS and PANSS scores, their performance level on tests of alertness, and both sustained and selective attention.

Type
Feature Articles
Information
CNS Spectrums , Volume 3 , Issue 10 , December 1998 , pp. 55 - 69
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Seeman, P, Wong, M, Lee, T. Dopamine receptor-block and nigral fiber-impulse blockade by major tranquilizers. Fed Proc. 1974;33:246.Google Scholar
2.Creese, I, Burt, DR, Snyder, SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481–483.Google Scholar
3.Bilder, MR. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry. 1997;42:255–264.Google Scholar
4.Stip, E. Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy. Can J Psychiatry. 1996;41(suppl 2):S27–S34.CrossRefGoogle ScholarPubMed
5.Clark, CR, Geffen, GM, Geffen, LB. Catecholamines and attention. I: animal and clinical studies. Neurosci Biobehav Rev. 1987;11:341–352.Google Scholar
6.Clark, CR, Geffen, GM, Geffen, LB. Catecholamines and attention. II: pharmacological studies in normal humans. Neurosci Biobehav Rev. 1987;11:353–364.Google Scholar
7.Lussier, I, Stip, E. Relations entre systémes neurochimiquement définis et la mémoire: problémes posés par la démence de type Alzheimer. J Psychiatry Neurosci. 1995;204:9–66.Google Scholar
8.Goldberg, TE, Greenberg, RD, Griffin, SJ, et al.The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 1993;162:43–48.Google Scholar
9.Spohn, HE, Strauss, ME. Relation of neuroleptic and anticholinergic medication to cognitive functioning in schizophrenia. J Abnorm Psychol. 1990;98:367–380.Google Scholar
10.Cornblatt, B, Obuchowski, M, Andreasen, A. Attention, clinical symptoms and pharmacology in schizophrenia. Schizophr Res. 1997;24:212.Google Scholar
11.Opler, LA, Kay, SR, Rosado, V, et al.Positive and negative syndromes in chronic schizophrenic inpatients. J Nerv Merit Dis. 1984;172:317–325.Google Scholar
12.Bilder, RM, Mukherjee, S, Reider, RO, et al.Symptomatic and neuropsychological components of defect states. Schizophr Bull. 1985;11:51–59.Google Scholar
13.Cornblatt, BA, Lenzenweger, F, Dworkin, RH, et al.Positive and negative schizophrenic symptoms, attention, and information processing. Schizophr Bull. 1985;11:387–408.Google Scholar
14.Walker, E, Harvey, P. Positive and negative symptoms in schizophrenia: attentional performance correlates. Psychopathology. 1986;19:294–302.Google Scholar
15.Andreasen, NC, Flaum, M, Swayze, VW, et al.Positive and negative symptoms in schizophrenia: a critical reappraisal. Arch Gen Psychiatry. 1990;47:615–621.Google Scholar
16.Hain, C, Maier, W, Klingler, T. Positive/negative symptomatology and experimental measures of attention in schizophrenic patients. Psychopathology. 1993;26:62–68.CrossRefGoogle ScholarPubMed
17.Shallice, T. From Neuropsychohgy to Mental Structure. New York, NY: Cambridge University Press; 1988.Google Scholar
18.Warrington, EK, Weiskrantz, L. New method in testing long-term retention with special reference to amnesic patients. Nature. 1968;217:972–974.CrossRefGoogle ScholarPubMed
19.Squire, LR. Mechanisms of memory. Science. 1986;232:1612–1619.Google Scholar
20.Baddeley, A. Working Memory. Oxford, England: Oxford University Press; 1986.Google Scholar
21.Treisman, A, Sato, S. Conjunction search revisited. J Exp Psychol Human Perception Perform. 1990;16:459–478.Google Scholar
22.Posner, MI, Petersen, SE. The attention system of the human brain. Am Rev Neurosci. 1990;13:25–42.Google Scholar
23.Goldman-Rakik, PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6:348–357.Google Scholar
24.Vendrell, P, Junque, C, Pujol, J, Jurado, MA, Molet, J, Grafman, J. The role of prefrontal regions in the Stroop task. Neuropsychqlogia. 1995;33:341–352.Google Scholar
25.Berman, KF, Ostrem, JL, Randolph, C, et al.Physiological activation of a cortical network during performance of the Wisconsin Card Sorting Test: a positron emission tomography study. Newopsychologia. 1995;33:1027–1046.Google Scholar
26.Squire, LR, Knowlton, B, Musen, G. The structure and organization of memory. Ann Rev Psychol. 1993;44:453–495.Google Scholar
27.Weinberger, DR, Berman, KF, Suddath, R, Torrey, EF. Evidence of dysfunction of the prefrontallimbic network in schizophrenia-magnetic resonance imaging and regional blood flow study of discordant monozygotic twins. Am J Psychiatry. 1992;149:890–897.Google Scholar
28.Lieberman, JA. Understanding the mechanism of action of antipsychotic drugs. Br J Psychiatry. 1993;163:7–18.Google Scholar
29.Meltzer, HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994;55B:47–52.Google Scholar
30.Seeman, P, Van Tol, HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci. 1994;15:264–270.CrossRefGoogle ScholarPubMed
31.Hagger, C, Buckley, P, Kenny, JT, Freidman, L, Ubogy, D, Meltzer, HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 1993;34:702–712.CrossRefGoogle ScholarPubMed
32.Buchanan, RW, Holstein, C, Breier, A. The comparative efficiency and long-term effect of clozapine treatment on neu-ropsychological test performance. Biol Psychiatry. 1994;36:717–725.Google Scholar
33.Zahn, TP, Pickard, D, Hier, RJ. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res. 1994;13:133–144.Google Scholar
34.Bartus, RT, Dean, RD, Beer, B, Iippa, AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–417.Google Scholar